Inventor · disambiguated record
Bernd Liepold
Also filed as: LIEPOLD BERND · LIEPOLD BERND HARALD
28 granted patents·25 pending applications·170 citations·filing 1999–2024
96Inventor score
Top patents by PatentIndex Score
53 records- 0196US11633396B2Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-oneKUDOS PHARM LTD·Filed 2022·Granted Apr 25, 2023·8 cites·30 claims
- 0295US8268349B2Solid pharmaceutical dosage formROSENBERG JOERG·Filed 2012·Granted Sep 18, 2012·15 cites·7 claims
- 0393US6599528B1Mechanically stable pharmaceutical presentations form containing liquid or semisolid surface-active substancesABBOTT GMBH & CO KG·Filed 2000·Granted Jul 29, 2003·50 cites·6 claims
- 0490US12178816B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2024·Granted Dec 31, 2024·0 cites·30 claims
- 0590US12144810B1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2024·Granted Nov 19, 2024·0 cites·30 claims
- 0690US8475842B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneBECHTOLD MICHAEL KARL·Filed 2009·Granted Jul 2, 2013·21 cites·10 claims
- 0789US8377952B2Solid pharmaceutical dosage formulationABBOTT LAB·Filed 2005·Granted Feb 19, 2013·4 cites·35 claims
- 0888US9333204B2Solid antiviral dosage formsABBVIE INC·Filed 2015·Granted May 10, 2016·5 cites·15 claims
- 0988US8399015B2Solid pharmaceutical dosage formROSENBERG JOERG·Filed 2011·Granted Mar 19, 2013·3 cites·31 claims
- 1088US8025899B2Solid pharmaceutical dosage formABBOTT LAB·Filed 2004·Granted Sep 27, 2011·14 cites·14 claims
- 1186US12048695B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2023·Granted Jul 30, 2024·0 cites·10 claims
- 1286US11975001B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2023·Granted May 7, 2024·0 cites·13 claims
- 1385US9744170B2Solid antiviral dosage formsABBVIE INC·Filed 2016·Granted Aug 29, 2017·3 cites·20 claims
- 1484US8691878B2Solid pharmaceutical dosage formABBVIE INC·Filed 2012·Granted Apr 8, 2014·2 cites·20 claims
- 1582US8333990B2Solid pharmaceutical dosage formROSENBERG JOERG·Filed 2010·Granted Dec 18, 2012·1 cites·23 claims
- 1679US9060986B2Delivery system for sustained release of a calcium-channel blocking agentBREITENBACH JORG·Filed 2010·Granted Jun 23, 2015·13 cites·8 claims
- 1779US2024197757A1Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitorABBVIE DEUTSCHLAND·Filed 2023·Application pending·0 cites
- 1878US2022249474A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneKUDOS PHARM LTD·Filed 2021·Application pending·0 cites
- 1973US10105365B2Solid antiviral dosage formsABBVIE INC·Filed 2017·Granted Oct 23, 2018·1 cites·61 claims
- 2073US8686026B2Solid compositionsLIEPOLD BERND·Filed 2011·Granted Apr 1, 2014·7 cites·21 claims
- 2172US2020323847A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2020·Application pending·0 cites
- 2272US2022110951A1Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitorABBVIE DEUTSCHLAND·Filed 2021·Application pending·0 cites
- 2372US2014179721A1Solid pharmaceutical dosage formABBVIE INC·Filed 2014·Application pending·0 cites
- 2471US2008299203A1Solid Pharmaceutical Dosage FormulationROSENBERG JOERG·Filed 2008·Application pending·0 cites
- 2570US2021093649A1Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitorABBVIE DEUTSCHLAND·Filed 2020·Application pending·0 cites
- 2669US2019365751A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2018·Application pending·0 cites
- 2768US9642796B2Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitorPACKHAEUSER CLAUDIA·Filed 2010·Granted May 9, 2017·2 cites·22 claims
- 2867US9402909B2Pharmaceutical dosage form comprising polymeric carrier compositionABBVIE DEUTSCHLAND·Filed 2014·Granted Aug 2, 2016·1 cites·10 claims
- 2965US9078921B2Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing sameRosenberg Jörg·Filed 2007·Granted Jul 14, 2015·1 cites·20 claims
- 3065US8309613B2Solid pharmaceutical dosage formROSENBERG JOERG·Filed 2010·Granted Nov 13, 2012·0 cites·18 claims
- 3165US2018133216A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2017·Application pending·0 cites
- 3264US2017173010A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2017·Application pending·0 cites
- 3363US2019269704A1Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitorABBVIE DEUTSCHLAND·Filed 2019·Application pending·0 cites
- 3463US2007249643A1Solid pharmaceutical dosage formROSENBERG JOERG·Filed 2007·Application pending·0 cites
- 3563US2014066447A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2013·Application pending·0 cites
- 3662US2013004578A1Solid Pharmaceutical Dosage FormulationABBVIE INC·Filed 2012·Application pending·0 cites
- 3758US6599931B1Test system for characterizing the compatibility of bioactive substances and polyvinylpyrrolidoneABBOTT GMBH & CO KG·Filed 1999·Granted Jul 29, 2003·19 cites·5 claims
- 3858US2016008473A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2015·Application pending·0 cites
- 3958US2011182891A1Pharmaceutical dosage form comprising polymeric carrier compositionABBOTT GMBH & CO KG·Filed 2009·Application pending·0 cites
- 4057US2008181948A1Solid pharmaceutical dosage formulationsABBOTT LAB·Filed 2007·Application pending·0 cites
- 4157US2017189426A1Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitorABBVIE INC·Filed 2017·Application pending·0 cites
- 4252US10653625B2Production of dosage forms comprising a solid dispersion of a microcrystalline agentROSENBERG JOERG·Filed 2006·Granted May 19, 2020·0 cites·13 claims
- 4351US2015141351A1Solid Pharmaceutical CompositionsABBVIE DEUTSCHLAND·Filed 2014·Application pending·0 cites
- 4447US9616130B2Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing sameABBVIE DEUTSCHLAND·Filed 2015·Granted Apr 11, 2017·0 cites·20 claims
- 4546US8293374B2Test system for evaluating the compatibility of biologically active substances with copolymersBREITENBACH JOERG·Filed 2003·Granted Oct 23, 2012·0 cites·9 claims
- 4646US2010143459A1Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitorABBOTT GMBH & CO KG·Filed 2007·Application pending·0 cites
- 4745US2014171481A1Solid compositionsABBVIE INC·Filed 2014·Application pending·0 cites
- 4844US2005048112A1Solid pharmaceutical dosage formFiled 2003·Application pending·0 cites
- 4943US2002151578A1Formulation based on lipoic acid, process for its production and the use of this formulation for oral administration of lipoic acidFiled 2002·Application pending·0 cites
- 5042US9594073B2Test solvent for evaluating the compatibility of biologically active substances and graft copolymersBreitenbach Jörg·Filed 2011·Granted Mar 14, 2017·0 cites·13 claims
Showing the top 50 of 53 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →